Skip to main content
AmigoFish

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

From The Top Line · · 13 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most appropriate treatment. In this episode of The Top Line, host Kelly Hogan is joined by Susanne Munksted, chief growth officer at Diaceutics, and Jordan Clark, chief customer officer, to discuss why many diagnostic-driven therapies still fail to reach their full potential.

Drawing on findings from Diaceutics' practice gap studies, the conversation explores where patients are being lost across the diagnostic pathway and why improvements in testing have not always translated into better treatment decisions. The guests discuss increasing healthcare complexity, expanding biomarker requirements and the challenges clinicians face when making treatment decisions under time pressure.

See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.

Back to The Top Line · Report a problem